There has been a collaborative global effort to construct novel therapeutic and prophylactic approaches to SARS-CoV-2 management. Although vaccine development is crucial, acute management of newly infected patients, especially those with severe acute respiratory distress syndrome, is a priority. Herein we describe the rationale and potential of repurposing a dual plasmid, Vigil (pbi-shRNA furin -GM-CSF), now in Phase III cancer trials, for the treatment of and, in certain circumstances, enhancement of the immune response to SARS-CoV-2.
All Keywords
【저자키워드】 COVID-19, SARS-CoV-2, furin, GM-CSF, vigil, 【초록키워드】 Treatment, Vaccine development, immune response, Cancer, Prophylactic, management, therapeutic, trials, acute respiratory distress, Plasmid, phase, infected patients, syndrome, effort, approach, 【제목키워드】 virus, Coronavirus-2, acute respiratory syndrome, demise,
【저자키워드】 COVID-19, SARS-CoV-2, furin, GM-CSF, vigil, 【초록키워드】 Treatment, Vaccine development, immune response, Cancer, Prophylactic, management, therapeutic, trials, acute respiratory distress, Plasmid, phase, infected patients, syndrome, effort, approach, 【제목키워드】 virus, Coronavirus-2, acute respiratory syndrome, demise,